|
|
Article: BrainStorm Granted "Outperform" Rating by Murphy Analytics.
- Article from:
- Biotech Week
- Article date:
- November 11, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI) announced that Murphy Analytics, an equity research group, has Initiated Coverage on Brainstorm and granted Brainstorm with an Outperform Rating (see also BrainStorm Cell Therapeutics Inc.).
To view Murphy Analytic's report click the link below: http://www.murphyanalytics.com/uploads/BCLI_Initiation Rami Efrati, CEO of BrainStorm Cell Therapeutics, states, "We are very pleased with the quality of Murphy Analytics research coverage. The report provides serious investors with an in-depth understanding of our Company and what we believe to be a tremendous opportunity for creating outstanding returns for our ...